FINWIRES · TerminalLIVE
FINWIRES

生質燃料最新動態:原油價格上漲帶動主要原料價格走高

-- 週一,原油價格上漲提振了主要生物燃料原料價格,但出口疲軟的跡象限制了馬來西亞棕櫚油的漲幅。 芝加哥期貨交易所(CBOT)5月大豆油合約上漲1.16%,至每磅67.87美分,美國強勁的生物燃料計畫為其提供了上漲動力。 然而,大豆供應充足令大豆期貨承壓,CBOT 5月合約早盤下跌0.11%,至每蒲式耳11.75美元。 南美洲方面,報告顯示,截至4月初,巴西大豆收割進度已達82%,而阿根廷的進度僅2.4%。 美國農業部預計大豆種植面積為8,470萬英畝,低於預期。 價格報告機構MySteel表示:「市場仍處於南美供應充足與美國種植面積減少和需求改善之間的兩難。」該機構補充說,因此大豆價格可能將呈現區間震盪走勢。 在亞洲,馬來西亞衍生性商品交易所5月原棕櫚油合約在經歷一段波動後收盤上漲0.24%,至每噸4,511馬來西亞林吉特(1,134.99美元)。 6月合約上漲0.37%,至每噸4,555林吉特。 自2月下旬以來,不斷升級的地緣政治衝突推高了棕櫚油價格,但出口疲軟的跡象令今日的期貨價格承壓。 馬來西亞棕櫚油局局長艾哈邁德·帕爾維茲告訴《星報》,由於航運中斷導致出口利潤率下降,行業利潤可能無法完全反映價格飆升。 據報道,帕爾維茲表示,由於繞道非洲的航運路線將運輸時間延長了近兩週,馬來西亞在中東的主要市場也可能轉向附近的供應商。 據貨運調查機構稱,4月前10天,馬來西亞的貨運量較上月下降了30.7%至38.9%。如果4月出口持續走低,此趨勢可能會逆轉3月貨運量較上月成長40.7%的局面。 路透社引述Sunvin集團的阿尼爾庫馬爾巴加尼的話說,需要出口表現進一步強勁才能促進本月國內庫存下降。 《新海峽時報》引述聯昌證券的話說,如果需求持續旺盛且產量下降,馬來西亞4月份的庫存量可能從3月的230萬噸進一步降至220萬噸。 印尼將於7月1日起將生質柴油摻混比例從40%提高至50%,此舉或將提振該國的出口需求。 另一方面,由於化肥供應中斷和厄爾尼諾現象帶來的風險,該國的產量可能會下降。 在美國,紐約商品交易所(NYMEX)5月交割的乙醇期貨價格週五上漲0.52%,至每加侖約1.94美元。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA